These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2942409)

  • 1. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment.
    Elte JW; Bijvoet OL; Cleton FJ; van Oosterom AT; Sleeboom HP
    Eur J Cancer Clin Oncol; 1986 Apr; 22(4):493-500. PubMed ID: 2942409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clodronate for osteolytic metastases due to breast cancer.
    Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
    Biomed Pharmacother; 1988; 42(2):111-6. PubMed ID: 2971403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ; Bijvoet OL; van Oosterom AT
    Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of bisphosphonates in cancer patients.
    Body JJ; Coleman RE; Piccart M
    Cancer Treat Rev; 1996 Jul; 22(4):265-87. PubMed ID: 9025784
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
    Elomaa I; Blomqvist C; Porkka L; Holmström T; Laine H
    Cancer Treat Rep; 1984 Apr; 68(4):655-7. PubMed ID: 6231989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of malignant hypercalcaemia with clodronate.
    Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
    Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Osteolytic metastases of breast cancer and biphosphonates].
    Lortholary A; Alleaume C; Pein F; Larra F
    Rev Med Interne; 1992; 13(3):238-42. PubMed ID: 1410908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diphosphonates in the treatment of hypercalcemia].
    Delmas PD; Meunier PJ
    Rev Med Interne; 1984 Nov; 5(4):363-6. PubMed ID: 6240753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for the use of bisphosphonates in breast cancer.
    Kanis JA
    Acta Oncol; 1996; 35 Suppl 5():61-7. PubMed ID: 9142969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone-related protein and bone metastases.
    Guise TA
    Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and breast carcinoma.
    Lipton A
    Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in the treatment of malignant bone disease.
    Berenson JR; Lipton A
    Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone metastases and tumor-induced hypercalcemia.
    Body JJ
    Curr Opin Oncol; 1992 Aug; 4(4):624-31. PubMed ID: 1511019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates in prostate carcinoma.
    Adami S
    Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the use of bisphosphonates in bone metastases.
    Kanis JA; McCloskey EV; Taube T; O'Rourke N
    Bone; 1991; 12 Suppl 1():S13-8. PubMed ID: 1954047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
    Clines GA; Guise TA
    Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.